Articles On Imugene (ASX:IMU)

Highlights IMU has received confirmation for receipt of AU$11 million R&D tax refund for the 2023 financial year. The refund is anticipated by January 2025. Funds will support the clinical development of Imugene's immuno-oncology...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

As most ASX investors would be aware, the stock market has had a very lucrative year over 2024 so far. As it currently stands, the S&P/ASX 200 Index (ASX: XJO) has gained a significant 11.6% or so over the year thus far. Thanks to this...

It's a big day for Core Lithium Ltd (ASX: CXO) shares today. Not because of any outsized share price moves. Though shares in the All Ordinaries Index (ASX: XAO) lithium stock are up a welcome 1% at time of writing, trading for 9.3 ce...

Income investors certainly have a lot of choice on the Australian share market. So much so, it can be hard to decide which ASX dividend stocks to buy over others. To narrow things down, let's look at a couple of buy-rated dividend stocks th...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made. For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels. W...

Fresh from news of a “complete response” from other clinical trials last week, Imugene has now dosed the first patient with a drug combination that seeks to expose and target difficult-to-treat solid cancers.

The ASX200 has been down 0.4% at 8,261 points. Investors reacted with disappointment to the latest Chinese stimulus measures released on the weekend. Declining iron ore and oil prices has adversely affected commodity stocks, as hopes of...

Highlights First patient has been dosed in the intratumoural combination arm of the OASIS trial. The patient with colorectal cancer was dosed at Northwestern University. As part of the OASIS trial, the company intends to expand to 10...

The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic end to the trading week this Friday, giving investors a tangible boost as we head into the weekend. After spending all day in positi...

In an Australian first, clinical cancer researcher and developer Imugene will launch its “azer-cel” trial against a difficult-to-treat form of non-Hodgkins lymphoma at Sydney’s Royal Prince Alfred Hospital.

Both Wesfarmers Ltd (ASX: WES) shares and Sigma Healthcare Ltd (ASX: SIG) shares offer investors exposure to the pharmacy sector. Wesfarmers may be best known for its divisions like Bunnings, Kmart, and Officeworks, but it also owns Aust...

The Mineral Resources Ltd (ASX: MIN) share price has been volatile in 2024 and is down nearly 45% this year. Shares have slipped nearly 28% in the past month alone, with investor confidence shaken by revelations into co-founder Chris El...

Imugene Ltd (ASX:IMU) has opened the first Australian site for its clinical trial testing a therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – a difficult form of non-Hodgkin’s lymphoma. The company will carry out...

The S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed below. Here's why they are charging...

Highlights The first Australian site for the azer-cel Phase 1b trial is now open. Patient recruitment will start at Royal Prince Alfred Hospital in Sydney in November 2024. The azer-cel Phase 1b trial is currently the only allogeneic...

The Core Lithium Ltd (ASX: CXO) share price is surging higher today. Shares in the All Ordinaries Index (ASX: XAO) lithium stock closed yesterday trading for 11 cents. In morning trade on Wednesday, shares are swapping hands for 11.8 ce...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 Index (ASX: XJO) endured a tough day of trading this Tuesday as ASX investors pulled back from the optimism that we saw yesterday to kick off the trading week. By the time the...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Dividends have played an integral role in many S&P 500 companies. The payouts serve as a stabilizing force in such stocks, and...

It's fair to say that ASX 300 property stock Lifestyle Communities Ltd (ASX: LIC) has not had a great year so far in 2024. As it stood yesterday afternoon, Lifestyle Communities shares were down a painful 53% or so this year. Yep, this prop...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In afternoon trade, the benchmark index is down 0.4% to 8,132.7 points. Four ASX shares that are not letting that hold them back are listed below. He...

Clinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete response” for one of its bile tract cancer trial therapy subjects in its CF33 MAST VAXINIA study.

ASX exchange-traded funds (ETFs) have surged in popularity over the past few years, especially among younger investors. They offer a quick and easy way to achieve instant diversification by purchasing a basket of ASX shares or internati...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Looking at Wall Street analysts' price targets can be a worthy exercise, because it may identify some stocks with huge upsides you...

Highlights In the Phase 1 MAST trial for VAXINIA, a bile tract cancer patient has maintained a complete response for over two years. The Bile Tract Cancer Expansion phase has cleared its first cohort with no dose limiting toxicities, a...

Those who own ASX shares face an existential trilemma: how much cash to hold, how to finance new investments, and when to sell existing ones. Cash has to come from somewhere to purchase new assets. Keeping cash on the sidelines is one w...

Imugene Ltd (ASX: IMU) shares are having a strong start to the session on Tuesday. At the time of writing, the ASX 300 stock is up 11% to 4.9 cents. Why is this ASX 300 stock jumping? The catalyst for today's strong gain has been the releas...

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has reported a significant achievement in its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial. The company announced that a patient with bile tract cancer has now maintaine...

Shares in the embattled Star Entertainment Group Ltd (ASX: SGR) extended losses on Monday and finished the session nearly 7% in the red. The stock now fetches 21 cents apiece, bringing losses to more than 20% over the past week and nearl...

The Woolworths Group Ltd (ASX: WOW) share price has dropped 25% since June 2023 and close to 20% from 28 August 2024. On Friday, it dropped to a 52-week low of $29.79. As the chart above shows, Woolworths' supermarket business has de...

Are you looking to supercharge your portfolio with some big returns? If you are, it could pay to listen to what brokers are saying about the ASX shares listed below. They have been named as buys and tipped to rise strongly from current leve...

The S&P/ASX 200 Index (ASX: XJO) is wrapping up the trading week on a decidedly sour note this Friday. At the time of writing, the ASX 200 has dropped by a painful 0.99% and is back below 8,100 points. But let's talk about what's going...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

The ASX200 has been down a third of a percent (0.32%) at 8,154 points. Consumer Staples continue to be the worst performing sector, down 1.7%, with well-known plays Woolworths (ASX:WOW), Bega Cheese (ASX:BGA) and Elders (ASX:ELD) all dra...

The AGL Energy Limited (ASX: AGL) share price fell 6.9% to an intraday low of $10.38 on Thursday. The ASX utilities stock has recovered a little to be trading at $10.49 at the time of writing, down 5.96%. The energy provider has not...

Two S&P/ASX All Ordinaries Index (ASX: XJO) ASX healthcare shares are making big moves today following the release of their quarterly performance updates. One is racing ahead of the 0.2% losses posted by the All Ordinaries Index (ASX: X...

The S&P/ASX 200 Index (ASX: XJO) is having another relatively poor session on Thursday. In afternoon trade, the benchmark index is down 0.2% to 8,164.1 points. Four ASX shares that are falling more than most today are listed below. Her...

The stock market is one of the best places to invest for long-term returns. That's why I'm not afraid of an S&P/ASX 200 Index (ASX: XJO) sell-off in 2024, 2025, or any other year. There are different buyers and sellers each day who...

Woolworths Group Ltd (ASX: WOW) shares had a difficult time on Wednesday and were sold off by investors. The retail giant's shares ended the session 6% lower at $30.81. This leaves them trading within touching distance of a 52-week low. Why...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Highlights Orphan Drug Designation (ODD) has been secured from the US FDA for VAXINIA (CF33-hNIS). Benefits of ODD include grant funding, tax credits, fee waivers, and seven years of market exclusivity following FDA approval. The MAST...

Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced solid tumour trials to treat the rare and insidious disease.

Appen Ltd (ASX: APX) shares have been on a meteoric rise, surging 260% higher in just seven weeks. Shares in the language technology data company were swapping hands at 43 cents per share on July 29, their lowest point in months. At...

The Appen Ltd (ASX: APX) share price is off to the races today. Shares in the All Ordinaries Index (ASX: XAO) AI stock closed yesterday trading for $1.29. In afternoon trade on Thursday, shares are swapping hands for $1.52 apiece, up 18...

DroneShield Ltd (ASX: DRO) shares are rebounding on Wednesday morning after a 7% decline yesterday. In morning trade, the counterdrone technology company's shares are up 7% to $1.33. This compares favourably to the 0.1% gain by the benchmar...